ok lets say 10% penetration rate for US market on diagnosed cohort = 370k sprits. Now obviously that is going to take considerable time - wot happen overnight.
500USDx 370k scripts x 12 months = $2.2B USD or $3.3M AUD
EBITDA at 30% = $1B AUD. Note 30% is reasonable for Biotech and even analyst report had much higher in proforma forecast >40% EBITDA percentage
note above does not take into account undiagnosed in US or Japna and Korea sales. Its massive potential
comparative is CSL - $13B revenue and return $3B EBITDA. CSL Share price is $300 with Market cap of $147B
BOT is market cap of >$700M. Ok not saying we are next CSL, but just trying to get perspective on the numbers that is being floated around and potential.
Please correct me if i am wrong and my maths is $hite or am missing something
BOT - Anything but charting, page-10479
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.3¢ |
Change
0.018(4.22%) |
Mkt cap ! $789.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.0¢ | 41.5¢ | $3.496M | 8.124M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 228367 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 144221 | 21 |
View Market Depth
| Last trade - 15.53pm 09/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |